Evaluation and Characteristics of a New Direct Compression Performance Excipient - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluation and Characteristics of a New Direct Compression Performance Excipient
The authors investigated the tableting properties of PanExcea MHC300G, a high-performance excipient.


Pharmaceutical Technology
Volume 35, Issue 3

References

1. D. McCormik, Pharm. Technol. 5, (4) 52–62 (2005) .

2. N.A. Armstrong, Encyclopedia of Pharmaceutical Technology, Informa Healthcare USA, Inc. (New York, Third Edition, 2006).

3. H.G. Kristensen and T. Schaefer, Drug Dev. and Ind. Pharm. 13, 803–872 (1987).

4. A.J. Hlinak, et al., J. of Pharm. Innov. 1, 12–17 (2006).

5. M. Jivraj, L.G. Martini, C.M. Thomson, Pharm. Sci. and Technol. Today, 3, 58–63 (2000).

6. R.J. Roberts, R.C. Rowe, Int. J. of Pharm. 36, 205–209 (1987).

7. K. van der Voort Maarschalk, G.K. Bolhuis, Pharm. Technol. 23, 34–46 (1999).

8. K. van der Voort Maarschalk et al., Int. J. of Pharm. 151, 27–34 (1997).

9. G.K. Bolhuis, N.A. Armstrong, Pharm. Dev. and Technol. 11, 111–124 (2006).

10. G. Bubb, Tablets and Capsules, 7, (2007).

11. IPEC–Americas, Frequently Asked Questions web page, http://ipecamericas.org/about/faqs/, accessed Feb. 16, 2011.

12. N. Deorkar, Tablets and Capsules, 8, 22–26 (2008).

13. L. Mīinea, J. Farina, M. Kallam, N. Deorkar, Pharm. Processing, Feb. 2009, http://www.pharmpro.com/Articles/2009/03/A-New-World-of-Excipients-for-Oral-Solid-Dosage-Formulation/, accessed Feb. 16, 2011.

14. S.K. Nachaegari, A.K. Bansal, Pharm. Technol. 28 (1) 52–64 (2004).

15. M.C. Gohel, P.D. Jogani, J. of Pharm. and Pharm. Sci. 8, 76–93 (2005).

16. C. Moreton, "Functionality and Performance of Excipients in a Quality-by-Design World: Parts 1–6," a series of papers published in each issue of vol. 12 of American Pharmaceutical Review (2009).

17. N. Deorkar, J. Farina, L. Mīinea, S. Randive, "Directly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof" PCT/US2008/011555 (Oct. 2008).

18. Mallinckrodt Baker, product profile for PanExcea MHC300G, http://www.mallbaker.com/Literature/Documents/PanExcea%20IR%20Product%20Profile%20Lit7001.pdf, accessed Feb. 16, 2011.

19. L. Mīinea, R. Mehta, J. Farina, N. Deorkar, "Granular Excipients Based on Microcrystalline Cellulose: DOE study of a lab-based scale high shear granulation process," poster presentation at "Excipient Fest Americas", (Puerto Rico, April 2008).

20. USP 34–NF 29 General Chapter <1174> "Powder Flow."

21. Carr, R. L. Chem. Eng. 72,163–168, 1965.

22. Hosokawa Micron, product profile for Hosokawa Micron Powder Characteristics Tester PT-S, http://www.hosokawa.co.uk/powdtest.php, accessed Feb. 16, 2011.

23. S.I.F. Badawy, D.B. Gray, M.A. Hussain, Pharm. Res. 23, 634–640 (2006).

24. T. Suzuki et al., J. of Pharm. and Pharmacol. 53, 609–616 (2001).

25. C.K. Tye, C. Sun, G.E. Amidon, J. of Pharm. Sci. 94, 465–472 (2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here